4SC has out-licensed and partnered drug candidates to several national and international pharma and biotech companies.
Licensed to BioNTech AG
Toll-like receptor 7 (TLR-7) is limited to immune cells and activates the immune system to kill cancer cells. The anti-tumor activity of 4SC’s immune stimulators has been demonstrated in several animal studies.
Journal of Immunotoxicology
|Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S, Rath S, Michel S, Baumgartner R.
J Immunotoxicol. 2009 Dec;6(4):257-65. doi: 10.3109/15476910903286733.